ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
University of Paris-Sorbonne
París, FranciaPublicacións en colaboración con investigadores/as de University of Paris-Sorbonne (8)
2023
-
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
Clinical Colorectal Cancer, Vol. 22, Núm. 1, pp. 100-110
2021
-
First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676
2018
-
CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. v84
2017
-
Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer
Annals of Oncology, Vol. 28, pp. iii135-iii136
-
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer, Vol. 82, pp. 16-24
2014
-
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
European Journal of Cancer, Vol. 50, Núm. 3, pp. 496-505
2013
-
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: Quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
The Lancet Oncology, Vol. 14, Núm. 3, pp. 236-243
2011
-
A phase 3 trial of bevacizumab in ovarian cancer
New England Journal of Medicine, Vol. 365, Núm. 26, pp. 2484-2496